New drugs, diagnostic approved for advanced melanoma

May 29, 2013

(HealthDay)—Two new drugs, Tafinlar (dabrafenib) and Mekinist (trametinib), have been approved by the U.S. Food and Drug Administration to treat advanced melanoma, the most dangerous form of skin cancer.

Melanoma, the leading cause of death from skin disease, is expected to be diagnosed in more than 76,000 people this year, and about 9,480 are expected to die from it, the FDA said Wednesday in a news release. Tafinlar is approved for people with an abnormality in the BRAF V600E gene, while Mekinist is approved for people with a mutation in either the BRAF V600E or V600K genes, the agency said.

A newly approved companion diagnostic, the THxID BRAF test, will help determine if a person has a mutation in either gene, the FDA said.

The most serious side effects reported in people getting Tafinlar included increased risk of a less severe form of skin cancer (cutaneous ), fever, , shaking chills, dehydration, and a rise in blood sugar, the agency said.

The most serious side effects of Mekinist included heart failure, , skin infection and loss of vision.

Both drugs also could cause infertility or harm a developing fetus, the FDA said.

Tafinlar and Mekinist are marketed by North Carolina-based GlaxoSmithKline. The THxID BRAF test is manufactured by bioMerieux, based in France.

Explore further: Research shows promising treatments against skin cancer

More information: To learn more about these approvals, visit the FDA.

Related Stories

Research shows promising treatments against skin cancer

June 4, 2012
Two new experimental treatments against advanced melanoma have shown promise in keeping the deadly skin cancer at bay, according to research presented in the United States on Monday.

Simponi approved for ulcerative colitis

May 15, 2013
(HealthDay)—Simponi (golimumab) injection has been approved by the U.S. Food and Drug Administration to treat adults with moderate-to-severe ulcerative colitis.

Uncommon BRAF mutation in melanoma sensitive to MEK inhibitor drug therapy

July 16, 2012
An uncommon mutation of the BRAF gene in melanoma patients has been found to respond to MEK inhibitor drugs, providing a rationale for routine screening and therapy in melanoma patients who harbor the BRAF L597 mutation.

New drug, Vemurafenib, doubles survival of metastatic melanoma patients

March 1, 2012
A report published this week in the New England Journal of Medicine shows that the 50 percent of metastatic melanoma patients with a specific genetic mutation benefit from the drug Vemurafenib – increasing median survival ...

FDA approves genetic test for lung cancer drug

May 14, 2013
The Food and Drug Administration says it approved a genetic test from Roche to help doctors identify patients who can benefit from a lung cancer drug made by Genentech.

FDA approves Procysbi for nephropathic cystinosis

May 2, 2013
(HealthDay)—Procysbi (cysteamine bitartrate) delayed-release capsules have been approved by the U.S. Food and Drug Administration to treat nephropathic cystinosis in children (6 years and up) and adults. Since it is intended ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.